Pfizer/BioNTech Says Booster Dose Is 95.6% Effective in Phase 3 Trial

Pfizer/BioNTech Says Booster Dose Is 95.6% Effective in Phase 3 Trial

Pfizer/BioNTech , Says Booster Dose Is , 95.6% Effective in Phase 3 Trial.

On October 21, Pfizer/BioNTech said that a booster dose of their coronavirus vaccine was found to have a high efficacy rate in a Phase 3 trial.

Pfizer/BioNTech said that a booster dose was 95.6% effective, "irrespective of age, sex, race, ethnicity or comorbid conditions.".

CNN reports that the trial included over 10,000 fully-vaccinated people ages 16 and older.

They randomly received either a 30-microgram booster dose of vaccine or a placebo.

Pfizer and BioNTech noted that the results showed a reduction of disease among those who had a booster shot versus those who did not.

The companies pointed out that these are the first results from a randomized, controlled COVID-19 vaccine booster trial.

These results provide further evidence of the benefits of boosters as we aim to keep people well-protected against this disease.

, Albert Bourla, Pfizer Chairman and CEO, via CNN.

In addition to our efforts to increase global access and uptake among the unvaccinated, we believe boosters have a critical role to play in addressing the ongoing public health threat of this pandemic, Albert Bourla, Pfizer Chairman and CEO, via CNN.

In addition to our efforts to increase global access and uptake among the unvaccinated, we believe boosters have a critical role to play in addressing the ongoing public health threat of this pandemic, Albert Bourla, Pfizer Chairman and CEO, via CNN.

We look forward to sharing these data with health authorities and working together to determine how they can be used to support the rollout of booster doses around the world, Albert Bourla, Pfizer Chairman and CEO, via CNN